Paula K. Cobb
Director/Board Member bij PROTHENA CORPORATION PLC
Vermogen: - $ op 29-02-2024
Profiel
Paula K.
Cobb is on the board of Prothena Corp.
Plc and NightstaRx Ltd.
and Chief Business Officer at Affinia Therapeutics, Inc.
She previously held the position of Chief Operating Officer for Decibel Therapeutics, Inc. and Senior Vice President-Rare Disease Group at Biogen, Inc.
Ms. Cobb received an undergraduate degree from Amherst College and an MBA from Harvard Business School.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
PROTHENA CORP. PLC
-.--% | 17-05-2023 | 0 ( -.--% ) | - $ | 29-02-2024 |
Actieve functies van Paula K. Cobb
Bedrijven | Functie | Begin |
---|---|---|
PROTHENA CORPORATION PLC | Director/Board Member | 01-07-2019 |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Director/Board Member | - |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Corporate Officer/Principal | 01-09-2020 |
Eerdere bekende functies van Paula K. Cobb
Bedrijven | Functie | Einde |
---|---|---|
DECIBEL THERAPEUTICS, INC. | Chief Operating Officer | 01-12-2019 |
NIGHTSTAR THERAPEUTICS PLC | Director/Board Member | 07-06-2019 |
BIOGEN INC. | Corporate Officer/Principal | 01-01-2016 |
Opleiding van Paula K. Cobb
Amherst College | Undergraduate Degree |
Harvard Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
BIOGEN INC. | Health Technology |
PROTHENA CORPORATION PLC | Health Technology |
DECIBEL THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Health Services |
Nightstar Therapeutics Ltd.
Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Health Technology |